Octaninef (Human Coagulation Factor Ix)

Human Coagulation Factor IX is a protein component of the intrinsic pathway of the coagulation cascade. When infused, it replaces the missing or deficient factor IX, enabling activation of factor X to Xa, which then leads to thrombin generation and fibrin clot formation, thereby normalizing hemostasis.

The dose of Octaninef is individualized and determined by the prescribing clinician based on the patient’s baseline factor IX activity, the severity of bleeding, and the intended clinical goal (on‑demand treatment or prophylaxis). The prescriber calculates the required units per kilogram and adjusts according to laboratory monitoring.

Safety data for Octaninef in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or while breastfeeding should only be considered when the potential benefit to the mother outweighs any potential risk to the fetus or infant, and it must be prescribed by a specialist.

To order Octaninef, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling if needed) and assists with import documentation.

Octaninef is a plasma‑derived factor IX concentrate, whereas alternative products include recombinant factor IX and extended‑half‑life recombinant variants. Plasma‑derived products contain a broader spectrum of plasma proteins and may have a different immunogenicity profile, while recombinant forms are produced without human plasma and often have longer half‑lives, potentially reducing infusion frequency.

Octaninef must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging until use, must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended in‑use period. Proper cold‑chain management is essential during transport.

Octaninef is administered intravenously, typically as a slow infusion into a peripheral or central vein. The infusion rate and volume are determined by the prescribing clinician based on the calculated dose and patient tolerance. Administration should be performed by trained healthcare professionals in a setting where vital signs can be monitored.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor IX, which can reduce efficacy, and rare but severe hypersensitivity reactions such as anaphylaxis. Thromboembolic events may also occur, especially if dosing exceeds recommended levels. Patients should be monitored closely for these events during and after infusion.

Octaninef should not be used in individuals with known hypersensitivity to any component of the product, including human plasma proteins. It is also contraindicated in patients who have experienced severe allergic reactions to previous factor IX concentrates. Use in patients with active disseminated intravascular coagulation should be avoided unless specifically indicated by a specialist.